Hims & Hers Health (NYSE:HIMS) Insider Irene Becklund Sells 4,490 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 4,490 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $141,435.00. Following the sale, the insider directly owned 6,790 shares in the company, valued at $213,885. This trade represents a 39.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Irene Becklund also recently made the following trade(s):

• On Tuesday, June 16th, Irene Becklund sold 7,573 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.25, for a total transaction of $229,083.25.

Hims & Hers Health Trading Up 1.6%

Hims & Hers Health stock opened at $31.97 on Thursday. The stock has a market cap of $7.40 billion, a P/E ratio of -355.22, a PEG ratio of 59.04 and a beta of 2.37. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The firm’s fifty day moving average price is $26.11 and its 200-day moving average price is $26.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HIMS has been the topic of several research reports. Bank of America lowered their price objective on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 26th. Truist Financial lifted their price objective on Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, May 22nd. Barclays reaffirmed an “overweight” rating and issued a $39.00 target price on shares of Hims & Hers Health in a research note on Wednesday. Evercore set a $24.00 target price on Hims & Hers Health in a research note on Tuesday, February 24th. Finally, TD Cowen reduced their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, March 27th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $29.37.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Barclays and other commentators see breakout potential after the Novo Nordisk partnership, citing faster revenue and EBITDA growth in the second half of 2026, helped by weight-loss offerings. HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership
• Positive Sentiment: Investors are also betting on Hims & Hers benefiting from the peptide market and upcoming FDA review, which could open another growth catalyst for the business. HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
• Positive Sentiment: Longer-term bullish coverage argues the Novo deal and international expansion support a path toward management’s 2030 targets of $6.5 billion+ in revenue and $1.3 billion+ in adjusted EBITDA. Hims & Hers: The Bull Case Remains Strong
• Neutral Sentiment: The stock has also been supported by discussion that short interest remains elevated, which could leave shares vulnerable to additional short-covering if momentum continues. Hims & Hers Enters A New Phase
• Negative Sentiment: Recent insider sales by executives, including COO Michael Chi and insider Irene Becklund, may create some caution, though the filings say the trades were tied to 10b5-1 plans and tax withholding from equity vesting. SEC filing for Michael Chi sale
• Negative Sentiment: Despite the upbeat narrative, prior quarterly results were weak, with only 4% revenue growth, declining margins, and a net loss, reminding investors that execution still needs to improve. Hims & Hers: The Bull Case Remains Strong

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after purchasing an additional 78,543 shares during the period. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the 1st quarter worth about $30,000. EverSource Wealth Advisors LLC grew its position in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after buying an additional 687 shares during the period. Amundi grew its position in shares of Hims & Hers Health by 5.3% in the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after buying an additional 522 shares during the period. Finally, California Public Employees Retirement System grew its position in shares of Hims & Hers Health by 9.5% in the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after buying an additional 29,471 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.